<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511364</url>
  </required_header>
  <id_info>
    <org_study_id>AGN-CIP-300</org_study_id>
    <nct_id>NCT04511364</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of AGN1 Treated Patients</brief_title>
  <acronym>CONFIRM EXT</acronym>
  <official_title>Long-term Follow-up in Osteoporotic Women Treated With Local Osteo-Enhancement in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AgNovos Healthcare, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AgNovos Healthcare, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a multi-center study within Europe in up to 60 patients treated with&#xD;
      the AGN1 LOEP Kit in CONFIRM. This will be a non-randomized and non-blinded study. The study&#xD;
      will collect long-term follow-up data on the safety and clinical performance of AGN1 LOEP.&#xD;
&#xD;
      To qualify, subjects must have previously consented, enrolled, and been treated with the AGN1&#xD;
      LOEP kit in CONFIRM (AgNovos Study PST-EU-101.1).&#xD;
&#xD;
      Follow-up evaluations will be conducted at 24, 36, 48 and 60 months from the date the subject&#xD;
      originally received the AGN1 LOEP treatment. Subjects will receive DXA and X-ray imaging at&#xD;
      the 24- and 60-month follow-up visits. The 36- and 48-month follow-up evaluations will be&#xD;
      conducted by phone. All timepoints will include general health and medical record review.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DXA score at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Change in DXA score of treated hip from baseline pre-AGN1 LOEP to 24 months post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in DXA score at 60 months</measure>
    <time_frame>60 months</time_frame>
    <description>Change in DXA score of treated hip from pre-AGN1 LOEP to 60 months post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip fracture incidence</measure>
    <time_frame>60 months</time_frame>
    <description>The incidence of hip fracture on the treated side during the follow-up period through 60 months post-AGN1 LOEP treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic bone formation</measure>
    <time_frame>60 months</time_frame>
    <description>Radiologic appearance of bone formation as assessed by X-ray at 24 and 60 months post-treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>60 months</time_frame>
    <description>The incidence of all serious adverse events during follow-up determined to be at least possibly related to the procedure and/or device through 60 months post-AGN1 LOEP treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>AGN1 treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical imaging is performed during the 24 and 60 month follow-up visits</intervention_name>
    <description>X-ray and DXA scan</description>
    <arm_group_label>AGN1 treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject had previously enrolled in CONFIRM and received AGN1 LOEP treatment.&#xD;
&#xD;
          -  Subject has willingness, ability, and commitment to participate in baseline and&#xD;
             follow-up evaluations for the full length of the study.&#xD;
&#xD;
          -  Subject is capable of giving written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject was withdrawn from CONFIRM.&#xD;
&#xD;
          -  Subject has severe comorbidity or poor general physical/mental health that, in the&#xD;
             opinion of the Investigator, will not allow the subject to be a good study candidate.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo De Schepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Nikolaas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Lowe</last_name>
    <phone>+12407536416</phone>
    <email>alowe@agnovos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joris Coteur</last_name>
    <phone>0032473252806</phone>
    <email>jcoteur.consultant@agnovos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Bulterys</last_name>
      <email>koen.bulterys@telenet.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Howe JG, Hill RS, Stroncek JD, Shaul JL, Favell D, Cheng RR, Engelke K, Genant HK, Lee DC, Keaveny TM, Bouxsein ML, Huber B. Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study. Osteoporos Int. 2020 May;31(5):921-929. doi: 10.1007/s00198-019-05230-0. Epub 2019 Dec 4.</citation>
    <PMID>31802158</PMID>
  </reference>
  <reference>
    <citation>Stroncek JD, Shaul JL, Favell D, Hill RS, Huber BM, Howe JG, Bouxsein ML. In vitro injection of osteoporotic cadaveric femurs with a triphasic calcium-based implant confers immediate biomechanical integrity. J Orthop Res. 2019 Apr;37(4):908-915. doi: 10.1002/jor.24239. Epub 2019 Mar 20.</citation>
    <PMID>30793358</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local osteo-enhancement procedure</keyword>
  <keyword>hip fracture/prevention and control</keyword>
  <keyword>calcium phosphate</keyword>
  <keyword>calcium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

